Chiang Ling Li

Data privacy/cybersecurity

• US infection prevention company in $3.6B  acquisition of global healthcare provider – China data privacy due diligence  for deal involving infection prevention products and services.
• Japanese pharmaceutical company in $3B biopharma  alliance – Regulatory and data privacy due diligence for late-stage biopharma  acquisition and US healthcare tech partnership.
• Global investment bank on China data privacy –  Analysis of cross-border data transfers to cloud systems under cybersecurity  laws.
• French cosmetics company on internal social network  – Data privacy compliance for employee communication platform.
• Global tech company on China compliance – Review of  data security and privacy laws for international operations.
• Japanese biopharma company in US urological  therapies acquisition – China data privacy due diligence for remaining stake  purchase.
• International beauty company on digital  transformation – Data retention policies and blockchain implementation for  supply chain transparency.
• Financial advisory firm on cybersecurity compliance  – Internal data privacy program development and risk mitigation.
• US private equity firm in biomarker services  acquisition – Data privacy due diligence for Belgian and Canadian life  sciences targets.
• US pharmaceutical company on data breach response –  Incident reporting and compliance plan following patient data compromise.
• Global pharma company on data governance –  Implementation of unified structure for clinical, sales, and employee data.
• US healthcare services company in $6.1B acquisition  of Irish medtech – Regulatory and data privacy review for digital heart  monitoring and nutritional care businesses.
• US health system provider on mobile asthma app –  IP, clinical trial, and cross-border data transfer compliance for connected  medical devices.
• US life sciences company on China distribution  strategy – Regulatory review covering pharmaceutical packaging, bonded zones,  data encryption, and anti-monopoly pricing.
• European medical device company on ISO  certification – Information security compliance, including data privacy,  encryption, and telecom regulations.
• Fortune 50  pharma company on data breach response – Incident management and statutory  reporting after patient data exposure.

‍

• European  heavy machinery company in Suzhou Intermediate People’s Court patent abuse  case – Defence against wrongful patent claims involving third-party  technology and Chinese national standards.
• Japanese multinational in US pharmaceutical  acquisition – Regulatory due diligence, contract negotiation, and  post-closing compliance for therapeutic candidates targeting bacterial  pneumonia, overactive bladder, and prostate cancer.
• Multinational sporting brand in Supreme People’s  Court copyright litigation – Enforcement across 50 proceedings to reclaim  pirated trademarks, countering market disruption.
• European machinery company in Supreme People’s  Court patent non-infringement case – Precedent-setting judgment against  patent hijackers, later codified into Chinese law via 2020 Judicial  Interpretation.
• Global education testing organization in trademark  dilution case – Secured well-known mark status in China, with the ruling  published as a guiding case by the State Intellectual Property Office.